Chronic Pain Statistics in US 2026 | Patients, Costs & Facts

Chronic Pain in America 2026

Chronic pain has emerged as one of the most pressing and costly public health crises in the United States, affecting tens of millions of Americans and imposing a staggering economic burden that exceeds the combined costs of cancer, heart disease, and diabetes. According to the latest data from the Centers for Disease Control and Prevention (CDC) published in November 2024, 24.3% of US adults — approximately 60 million people — live with chronic pain lasting three months or longer, representing a significant increase from 20.4% in 2019 and 20.9% in 2021. Even more troubling, 8.5% of US adults (21 million people) experience high-impact chronic pain that frequently limits life or work activities, up from 7.4% in 2019 and 6.9% in 2021. These numbers tell only part of the story. The prevalence of chronic pain has risen by more than 19% in just four years, driven by an aging population, delayed healthcare access during the COVID-19 pandemic, changes in pain management guidelines, and growing recognition of chronic pain as a distinct disease rather than merely a symptom.

The human and economic toll is staggering. Research published by Johns Hopkins University estimates the annual cost of chronic pain in the United States at $560 billion to $635 billion, exceeding the yearly costs for cancer ($243 billion), heart disease ($309 billion), and diabetes ($188 billion) combined. More recent 2022-based estimates place the economic burden of managing chronic pain patients at $725 billion to $735 billion annually, with healthcare costs alone ranging from $447 billion to $735 billion depending on whether surgical procedures are included. Beyond direct medical expenses, chronic pain drives $299 billion to $335 billion in lost productivity through missed workdays, reduced work hours, and lower wages. Yet despite this massive burden, chronic pain remains undertreated and understudied — as of 2018, 96% of US medical schools did not require students to take courses on pain medicine, and significant disparities persist across racial, ethnic, socioeconomic, and geographic lines. As we enter 2026, the question is not whether chronic pain is a crisis, but whether the United States healthcare system can mobilize the resources, research, and policy changes needed to address it effectively before millions more Americans join the ranks of those living with daily, debilitating pain.

Interesting Facts: US Chronic Pain in 2026

Source: CDC National Health Interview Survey 2023 (NCHS Data Brief No. 518, Nov 2024); CDC MMWR 2021 Data (April 2023); Johns Hopkins University / Journal of Pain (2012); ISPOR 2022 Economic Analysis; U.S. Pain Foundation Fact Sheet (2024); AMA Opioid Report (Jan 2026); CDC Opioid Dispensing Data (Feb 2026)

The table above captures the most alarming realities of chronic pain in the United States in 2026. The single most striking figure is the 24.3% prevalence rate — nearly one in four American adults now lives with chronic pain, a proportion that has climbed nearly 20% in just four years. This translates to 60 million people experiencing pain on most days or every day for at least three months, with 21 million of those suffering high-impact chronic pain severe enough to restrict daily living and work activities. The $560 billion to $735 billion annual economic cost places chronic pain ahead of the nation’s most feared diseases — it costs more than cancer, heart disease, and diabetes combined, yet receives a fraction of the research funding and public attention those conditions command.

The demographic disparities are stark and troubling. American Indian and Alaska Native adults experience chronic pain at a rate of 30.7% — nearly triple the 11.8% rate among Asian Americans and far above the national average. Women suffer disproportionately, with a 26.4% prevalence rate compared to 22.0% among men. Age is a relentless driver — just 12.3% of adults aged 18–29 have chronic pain, but that figure climbs to 36.0% among those 65 and older, meaning more than one in three seniors lives with persistent pain. The 83% of high-impact chronic pain patients unable to work illustrates how pain doesn’t just hurt individuals — it removes productive workers from the labor force, strains disability systems, and perpetuates cycles of poverty. Perhaps most troubling is the at least twice the suicide risk carried by chronic pain patients, revealing how untreated or undertreated pain drives mental health crises and preventable deaths.

Overall Chronic Pain Prevalence in the US 2026

Source: CDC National Center for Health Statistics (NCHS) Data Brief No. 518 (November 2024); CDC MMWR April 2023 (2019–2021 Data); CDC Data Brief No. 390 (November 2020); National Academy of Medicine / Institute of Medicine (2016); U.S. Pain Foundation (2024)

The overall chronic pain prevalence in the United States has climbed relentlessly over the past decade, rising from approximately 20% in 2016 to 24.3% in 2023 — a 21.5% relative increase in just seven years. The absolute number of Americans living with chronic pain has surged from roughly 50 million in 2016 and 2019 to 60 million in 2023, an increase of 10 million people in four years. High-impact chronic pain — the most severe category, where pain frequently limits life or work activities — initially appeared to decline slightly from 7.4% in 2019 to 6.9% in 2021, likely reflecting pandemic-related delays in healthcare access and underreporting. However, by 2023, high-impact chronic pain had rebounded to 8.5%, representing 21 million Americans whose daily functioning is substantially restricted by pain, a 23% increase from the 2021 figure of 17.1 million.

These trends paint a troubling picture of a growing public health crisis. Sean Mackey, MD, PhD, of Stanford School of Medicine, who co-authored the CDC’s 2016 chronic pain analysis, told MedPage Today: “What is clear is we have an astounding and growing public health crisis of chronic pain. This crisis touches everyone and requires a broader public health approach to reverse this concerning trend.” Multiple factors drive the increase: an aging US population (seniors have triple the chronic pain rate of young adults), delayed or disrupted healthcare access during COVID-19, mental health deterioration during the pandemic that amplifies pain perception, changes in opioid prescribing guidelines that left some patients undertreated, and improved surveillance and recognition of chronic pain as a distinct condition. If current trajectories continue, the United States could see 62 million or more Americans living with chronic pain by 2026, with high-impact chronic pain approaching 9% of the adult population.

Chronic Pain Prevalence by Age in the US 2026

Source: CDC National Center for Health Statistics Data Brief No. 518 (November 2024); Statista / CDC MMWR 2021 Analysis

Age is the single strongest predictor of chronic pain prevalence in the United States, with rates climbing steeply and linearly across the lifespan. Among young adults aged 18 to 29, just 12.3% experience chronic pain and only 3.2% have high-impact chronic pain — relatively low rates that reflect the resilience and recovery capacity of younger bodies. By middle age (30–44 years), prevalence jumps to 18.0% for chronic pain and 5.7% for high-impact pain, nearly a 50% increase from the youngest cohort. The surge accelerates in late middle age and early senior years: among adults 45 to 64, more than one in four (27.4%) lives with chronic pain, and 10.1% — one in ten — experience high-impact pain that frequently limits daily activities.

The burden reaches its peak among seniors 65 and older, where 36.0% have chronic pain and 13.7% have high-impact chronic pain — meaning more than one in three older adults experiences persistent pain, and nearly one in seven faces pain severe enough to substantially restrict their ability to work, exercise, socialize, or perform routine tasks. Among the oldest old (85+ years), 2021 data showed chronic pain prevalence around 34%, suggesting a possible plateau or slight decline in the very oldest age groups, potentially due to survivor effects (those with the most severe health conditions may not survive to 85) or underreporting due to cognitive decline. The age gradient in chronic pain has profound implications for the future: as the Baby Boomer generation continues aging, the absolute number of Americans living with chronic pain will surge even if age-specific prevalence rates remain stable, placing unprecedented demands on the healthcare system, long-term care facilities, and family caregivers.

Chronic Pain Prevalence by Sex/Gender in the US 2026

Source: CDC National Center for Health Statistics Data Brief No. 518 (November 2024)

Women experience chronic pain at significantly higher rates than men across all age groups and severity levels in the United States. The 2023 CDC data shows 26.4% of women live with chronic pain compared to 22.0% of men, a 4.4 percentage point gap that translates to a 20% higher relative prevalence among women. The disparity is even more pronounced for high-impact chronic pain: 9.9% of women experience pain that frequently limits life or work activities, compared to just 7.1% of men — a 39% higher rate among women. These differences persist even after controlling for age, suggesting biological, hormonal, and social factors beyond simple demographic composition.

Multiple mechanisms contribute to the gender gap in chronic pain. Biological factors include sex differences in pain processing, hormonal influences on pain perception (estrogen and progesterone affect nociceptive pathways), and higher prevalence of pain-associated autoimmune conditions in women (fibromyalgia, lupus, rheumatoid arthritis). Psychosocial factors include higher rates of anxiety and depression among women (which amplify pain), greater exposure to interpersonal trauma and violence, and societal expectations that may make women more willing to report pain while men face pressure to minimize suffering. Healthcare system factors include historical undertreatment of women’s pain, dismissal of women’s pain complaints as “psychological” or exaggerated, and research gaps (most pain research historically used male subjects). The higher high-impact pain rate among women (9.9% vs. 7.1%) is particularly concerning, as it indicates women are not just more likely to experience chronic pain but more likely to experience pain severe enough to disrupt daily functioning, work capacity, and quality of life.

Chronic Pain Prevalence by Race/Ethnicity in the US 2026

Source: CDC National Center for Health Statistics Data Brief No. 518 (November 2024); CDC MMWR April 2023 (2019–2021 Analysis); U.S. Pain Foundation (2024)

Racial and ethnic disparities in chronic pain prevalence are stark and well-documented, with American Indian and Alaska Native (AI/AN) adults experiencing the highest burden at 30.7% chronic pain and 12.7% high-impact chronic pain — rates nearly triple those of Asian Americans and significantly above the national average of 24.3%. Non-Hispanic White adults have the second-highest prevalence at 26.5% overall and 9.3% high-impact pain, slightly above the national average. Non-Hispanic Black adults report 23.8% chronic pain prevalence, slightly below the national average, though their high-impact chronic pain rate of 10.0% is notably elevated, suggesting Black Americans may experience more severe or functionally limiting pain even if overall prevalence is lower.

Hispanic/Latino adults show substantially lower chronic pain rates at 17.1% overall and 5.8% high-impact pain, though research suggests this may reflect underreporting due to language barriers, cultural attitudes toward pain expression, or reduced healthcare access rather than genuinely lower pain burden. Most striking, Asian American adults report the lowest chronic pain prevalence of any major racial group at 11.8% overall and just 2.6% high-impact pain — less than half the national average. Research indicates this partly reflects cultural differences in pain reporting and healthcare-seeking behavior, though biological and lifestyle factors may also contribute.

The disparities extend beyond race alone. CDC’s 2021 analysis found adults identifying as bisexual experienced significantly higher chronic pain and high-impact chronic pain prevalence compared to heterosexual adults, likely reflecting minority stress, discrimination, and mental health challenges. Divorced or separated adults also showed elevated pain rates compared to married or never-married individuals. These patterns underscore how chronic pain intersects with social determinants of health — discrimination, economic hardship, healthcare access, occupational hazards, and psychosocial stress — making pain not just a medical problem but a social justice issue requiring comprehensive, equity-focused interventions.

Chronic Pain Prevalence by Urbanization Level in the US 2026

Source: CDC National Center for Health Statistics Data Brief No. 518 (November 2024); PMC Study (November 2024) on chronic pain prevalence trends in urban, suburban, rural areas

Chronic pain prevalence increases systematically with decreasing urbanization level, revealing a troubling rural-urban health disparity. Adults living in large central metropolitan areas (major cities) have the lowest chronic pain prevalence at 21.5% and high-impact chronic pain at 7.1% — both well below the national average. Moving outward to large fringe metro areas (suburbs of major cities), prevalence rises to 23.3% and 7.8%, still below the national average but approaching it. In medium or small metropolitan areas, chronic pain reaches 25.2% and high-impact pain 8.8%, slightly above the national average. The gap widens dramatically in nonmetropolitan (rural) areas, where 29.3% of adults experience chronic pain and 11.4% face high-impact pain — rates 36% higher than large central metro areas for chronic pain and 61% higher for high-impact chronic pain.

A 24-year longitudinal study published in 2024 examining adults aged 55 and older from 1998 to 2022 found even more alarming trends: chronic pain prevalence increased by 70% over those two and a half decades, with pain consistently highest in rural areas and lowest in urban areas. The study concluded that “rural-urban disparities have shifted over the course of the 21st century, potentially owing to changing composition and context in rural areas such as population aging and shifts in socioeconomic distribution.” Multiple factors drive the rural pain gap: limited healthcare access (fewer primary care providers, pain specialists, and physical therapists per capita), higher rates of physically demanding occupations (agriculture, mining, manufacturing), older age structures in rural communities as young people migrate to cities, higher poverty rates, lower educational attainment, and greater social isolation. The result is a vicious cycle where rural residents experience more pain, have fewer treatment options, face longer travel distances to specialists, and suffer worse outcomes — a disparity that demands targeted policy interventions, telemedicine expansion, and rural healthcare workforce development.

Economic Costs of Chronic Pain in the US 2026

Source: Johns Hopkins University / Journal of Pain (2012); ISPOR International Conference 2024 Presentation (2022 MarketScan data); U.S. Pain Foundation; CDC Fast Facts on Chronic Conditions (2025); NCBI Relieving Pain in America

The economic burden of chronic pain in the United States is staggering, eclipsing the costs of the nation’s most feared diseases. The landmark 2012 Johns Hopkins University study published in The Journal of Pain estimated the total annual cost at $560 billion to $635 billion in 2010 dollars, composed of $261 billion to $300 billion in incremental healthcare expenditures and $299 billion to $335 billion in lost productivity from missed workdays, reduced work hours, and lower wages. This cost is greater than the combined annual costs of heart disease ($309 billion), cancer ($243 billion), and diabetes ($188 billion) — yet chronic pain receives a fraction of the research funding, public awareness, and policy attention those conditions command.

Updated 2022 data presented at the ISPOR International Conference using the Merative MarketScan Commercial Claims and Medicare Supplemental Databases found the estimated annual economic burden of managing chronic pain patients at $725 billion, with direct healthcare costs (excluding surgical procedures) at $447 billion. Average per-patient annual costs were $23,705 for chronic pain patients compared to $16,494 for acute pain patients — a 44% higher cost for chronic pain. Critically, the analysis found that all-cause annual healthcare costs per patient were more than double for patients treated with opioids compared to those who did not receive opioids, reflecting both the higher severity of pain in opioid-treated patients and the additional monitoring, management, and complication costs associated with opioid therapy.

The cost distribution reveals who bears the burden: private insurers paid the largest share, ranging from $112 billion to $129 billion annually, while Medicare bore 25% of incremental costs ($66 billion to $76 billion), and individuals paid $44 billion to $51 billion in out-of-pocket expenditures. As the Johns Hopkins researchers concluded: “Because of its economic toll on society, the nation should invest in research, education, and training to advocate the successful treatment, management, and prevention of pain.” Yet despite these massive costs, chronic pain research remains underfunded, pain education in medical schools remains minimal, and access to multidisciplinary pain management remains limited, particularly in rural and underserved communities.

Opioid Use & Prescribing Patterns for Chronic Pain in the US 2026

Source: AMA 2025 Report on Substance Use (Jan 2026); CDC Opioid Dispensing Rate Maps (Feb 2026); NCHS National Health Statistics Reports No. 162 (Aug 2021); SingleCare (2025); STAT News (Dec 2024); Taylor & Francis Journal Study (2025)

Opioid prescribing for chronic pain has plummeted in the United States, falling 52% from a peak of 260.5 million prescriptions in 2012 to 125.7 million in 2024, according to the American Medical Association’s 2025 report. The national opioid dispensing rate dropped from 46.8 prescriptions per 100 persons in 2019 to 35.4 per 100 in 2024, reflecting a decade of guideline changes, prescription drug monitoring programs, prescriber education, and regulatory pressure following the opioid epidemic. Despite these dramatic reductions, 22% of adults with chronic pain still used prescription opioids in the last three months as of 2019 NCHS data (the most recent comprehensive survey), though this likely represents a smaller proportion today given continued prescribing declines.

Demographic patterns in opioid use for chronic pain reveal important disparities. Women with chronic pain (24%) were more likely to use prescription opioids than men (19%), possibly reflecting both higher pain prevalence and historical prescribing patterns. Opioid use peaked among middle-aged adults 45–64 (26%), the age group with high chronic pain prevalence and substantial work/family responsibilities driving demand for pain relief, while just 12% of young adults 18–29 and 22% of seniors 65+ with chronic pain used opioids. Geographic variation is extreme: Arkansas led the nation with 68.8 opioid prescriptions per 100 persons in 2024, while Hawaii had the lowest rate at just 21.0 — a more than three-fold difference reflecting regional prescribing cultures, pain management resource availability, and regulatory environments.

The sharp reduction in prescribing has created unintended consequences. A 2024 survey of 2,800 people with chronic pain found 90% reported delays or difficulties filling their opioid prescriptions, mainly due to pharmacy stock shortages caused by DEA production quotas. Patients with legitimate pain — including cancer pain and end-of-life care — increasingly face barriers to necessary medications. The AMA’s 2025 report notes that “many patients still face barriers to non-opioid pain treatments because of restrictive insurance coverage, leaving them in pain and with reduced function,” highlighting the gap between reduced opioid access and expanded access to alternatives like physical therapy, cognitive-behavioral therapy, interventional procedures, and non-opioid medications. The challenge for 2026 is balancing the imperative to prevent opioid misuse and addiction with the ethical obligation to adequately treat patients suffering from severe, chronic pain.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE